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Abstract
Background: The aim of this study was to review and compare types of reimbursement recommendations for
orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement
status of these drugs in the corresponding countries. Separate calculations were also performed for three
sub-groups: ultra-orphan drugs, oncology orphan drugs and other (non-ultra, non-oncology) orphan drugs.
Results: We reviewed drugs authorized by the European Medicine Agency (EMA) between 1 November 2002 and
30 September 2015. Among these, we identified 101 orphan drugs. Seventy-nine of them were assessed by eight
European HTA agencies. The average rates of positive, conditional and negative reimbursement recommendations
issued by these agencies were 55.7 %, 15.3 % and 29.0 %, respectively. On average, 21.2 % of EMA-authorized
orphan drugs were reimbursed in the eight European countries studied: 49.0 % of those with positive, 53.6 % of
those with conditional, and 16.0 % of those with negative reimbursement recommendations. In addition, 5.4 % of
orphan drugs that had not been assessed by any of the eight HTA agencies were also reimbursed. The shares of
oncology, ultra, and other orphan drugs that were assessed by HTA agencies were similar, with the lowest share
observed in ultra-orphan drugs (72 %) and the highest in other orphan drugs (80 %). In terms of reimbursement, 20
% of oncology orphan drugs, 25 % of ultra-orphan drugs and 21 % of other orphan drugs were reimbursed.
Conclusions: Reimbursement of orphan drugs does not always correspond to the type of HTA recommendation.
While the highest rate of reimbursement is observed (unsurprisingly) among drugs with positive or conditional
recommendation, a high rate of reimbursement (11 %) is also observed among ultra-orphan drugs that had never
been assessed by any HTA agency.
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Background
While the definition of orphan diseases varies between
countries, it is generally accepted that diseases affecting
between 1 and 8 persons per 10 000 are regarded as or-
phan or rare diseases. Within the European Union (EU),
orphan conditions are defined by the EMA as life-
threatening or chronically debilitating conditions that
affect no more than 5 in 10 000 people (which is equiva-
lent to approximately no more than 250 000 in the EU
(for each condition)) [1]. Making recommendations on
the reimbursement of orphan drugs may be difficult for
European Health Technology Assessment (HTA) agen-
cies because of the lack of sufficient clinical and cost
data. Prices of orphan drugs are often high, when we
compare them with prices of non-orphan drugs, due to
small therapy populations. As a result, decisions on the
public reimbursement and the number of reimbursed or-
phan drugs vary between EU member states.
Almost all of the eight European HTA agencies issued
in the period of the study (from the beginning of August
2015 till the end of December 2015) three types of rec-
ommendations: positive, partially positive (conditional)
and negative. The Dutch HTA agency did not issue
negative recommendations while the Swedish one did
not issue partially positive recommendations. Informa-
tion on the types of recommendations issued in the eight
countries is summarized in Table 1.
The aim of this study was to evaluate the relationship
between the reimbursement recommendations of HTA
agencies in eight countries in Europe and the reimburse-
ment status of orphan drugs in these countries, i.e. the
accessibility of such drugs for patients. In this study we
answered the question if the positive recommendation
of a HTA agency translates to the positive reimburse-
ment decision in case of orphan drugs.
The study covers the following countries and HTA agen-
cies: Germany - G-BA (Gemeinsamer Bundesausschuss),
France – HAS (Haute Autorité de Santé); the Netherlands
– ZIN (Zorginstituut Nederland;), Poland – AOTMiT
(Agencja Oceny Technologii Medycznych i Taryfikacji;);
Sweden – TLV (Dental and Pharmaceutical Benefits
Agency), and three of the four countries of the United
Kingdom (England – NICE (National Institute for Health
and Care Excellence), Scotland – SMC (Scottish Medicines
Consortium), and Wales – AWMSG (All Wales Medicines
Strategy Group).
Methods
The analysis was based on a review of the Orphanet
database. During the first stage of this review, we identi-
fied all EMA-authorized drugs that were designated as
orphan drugs. The review covered drugs authorized be-
tween 1 November 2002, which is when the EMA regis-
tered the first orphan drug, and 30 September 2015. For
all identified orphan drugs, we collected the following
information publicly available on chosen agencies` web-
sites in each of the eight countries: (1) was it assessed by
the HTA agency? (2) what type of reimbursement rec-
ommendation (positive, conditional, or negative; see
Table 1) was issued by the HTA agency for this particu-
lar drug? and (3) is the drug actually reimbursed? The
same data was then collected separately for three sub-
groups of orphan drugs: oncology orphan drugs, ultra-
orphan drugs, and non-ultra and non-oncology orphan
drugs.
Following the National Institute for Health and Care
Excellence (NICE) definitions, we have used the follow-
ing disease prevalence rates for including a drug in our
analysis: prevalence of less than 5 per 10 000 for orphan
drugs and less than 1 per 50 000 for ultra-orphan drugs
[1]. Information on the prevalence of diseases (i.e. classi-
fication as an orphan disease) was taken from the
Orphanet database and information on the indications
for all selected orphan drugs was taken from the EMA’s
website (http://www.ema.europa.eu/ema).
Results
We have identified 101 EMA-authorized orphan drugs
in the period studied. The eight HTA agencies evaluated
between 19.8 % and 74.3 % of all identified orphan
drugs. The HAS (France) assessed the highest number
of orphan drugs (75), while the NICE (England) assessed
only 20 (Fig. 1). Among the 101 orphan drugs identified,
22 (22 %) have not been assessed by any of eight HTA
agencies.
The average rates of positive, conditional, and negative
recommendations issued by the HTA agencies were 55.7
%, 29.0 %, and 15.3 %, respectively. The highest rate of
positive recommendations was found in Germany (100
%), and the lowest in the Netherlands (13.2 %). However,
the Dutch ZIN agency issued 73.7 % of conditional rec-
ommendations, which is the highest rate of conditional
recommendations among the eight HTA agencies
(Table 2).
Overall, it appears that the higher the number of
assessed drugs, the lower the probability of positive and
conditional HTA recommendations (Fig. 2).
The analysis does not warrant any statements about
causal relationship between the existence of special HTA
criteria and the share of positive and/or conditional
HTA recommendations or the number of reimbursed
orphan drugs. However, out of the three countries that
have special HTA criteria for orphan drugs (France,
Germany and Scotland), two (France and Germany) have
very high rates of positive and conditional HTA recom-
mendations for such drugs (Figs. 2 and 3).
Countries that have special criteria for orphan drugs
in the reimbursement process seem to have higher
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shares of orphan drugs (as a share of all assessed orphan
drugs) that are actually reimbursed – as a share of all
assessed orphan drugs (Germany, Netherlands, Sweden;
Fig. 4). The existence of special criteria for orphan drugs
in the reimbursement process seems to play a lesser role
for non-assessed orphan drugs (Fig. 5). The existence of
special criteria for orphan drugs in the HTA and reim-
bursement processes may therefore have some impact
on the access to such drugs for patients.
If all positive HTA recommendations translated into
actual reimbursement, the Netherlands and Poland
would have the lowest number of reimbursed orphan
Table 1 Types of HTA recommendations for orphan drugs issued in the analyzed period
Country Types of positive recommendations issued Types of partially positive / conditional
recommendations issued
Types of negative recommendations
issued
Germany - Major additional clinical benefit
- Significant additional clinical benefit
- Marginal additional clinical benefit
- Additional clinical benefit not quantifiable - No additional clinical benefit
- Lower additional clinical benefit
France - Major improvement of medical benefit
- Important improvement of medical benefit
- Moderate improvement of medical benefit
- Minor improvement of medical benefit - No improvement of medical benefit
Netherlands - Inclusion on List 1Bb – non-interchangeable
drug with added therapeutic value
- Inclusion on List 1Bb with financial access
arrangement
- Inclusion on List 1Aa – interchangeable
drug with equivalent therapeutic value
Not issued
Poland - Major additional clinical benefit
- Significant additional clinical benefit
- Marginal additional clinical benefit
- Additional clinical benefit not quantifiable
- Minor improvement of medical benefit,
high price
- Not recommended
Sweden - Major additional clinical benefit
- Significant additional clinical benefit
- Marginal additional clinical benefit
Not issued - No improvement of medical benefit
and very high cost
UK-England - Recommended - Recommended for restricted use
- Recommended for restricted use with
Patient Access Scheme
- Not recommended (or not
recommended because of no
submission)
UK-Wales - Recommended - Recommended for restricted use
- Recommended for restricted use with
Patient Access Scheme
- Not recommended (or not
recommended because of no
submission)
UK-
Scotland
- Recommended
- Recommended with Patient Access Scheme
- Recommended for restricted use
- Recommended for restricted use with
Patient Access Scheme
- Not recommended (or not
recommended because of no
submission)
Sources: Websites of HTA agencies of the eight countries included in the table
Notes: aList 1A includes generics, parallel imported medicines and new dosages of medicines that are already included in the reimbursement list. A shortened
reimbursement procedure is possible for such drugs, whereby the Ministry of Health, Welfare and Sport decides on the inclusion of the drug in the Medicine
Reimbursement System without the input of the Health Care Insurance Board; 90% of the medicines in this category are fully reimbursed. Products in this
category are clustered and reimbursed at an average price. bProducts which cannot be clustered, but are reimbursed at the market price, are published on List 1B.
Conditions for including a medicine in List 1B are based on the assessment of the therapeutic value and cost-effectiveness. If the therapeutic value of the medi-
cine is too low, it will not be eligible for reimbursement. Maximum wholesale prices are the only cap on the reimbursement price
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Fig. 1 Share (%) of orphan drugs assessed by HTA agency, by country. Source: Authors’ own calculations based on information from the websites
of the eight HTA agencies
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Table 2 Number and share (%) of assessed and reimbursed orphan drugs by type of HTA recommendation, by country
Countrya Assessed
orphan
drugs (out
of 101)
Assessed orphan drugs Reimbursed orphan drugs
Positive Conditional Negative Assessed orphan drugs Not
assessed
orphan
drugs
Total number Out of 101 Out of assessed drugs Positive Conditional Negative
England 20 % 20 60 % 12 5 % 1 35 % 7 13 13 % 65 % 25 % 3 0 % 0 14 % 1 11 % 9
Germany 25 % 25 100 % 25 0 % 0 0 % 0 20 20 % 80 % 76 % 19 0 % 0 0 % 0 1 % 1
Poland 36 % 36 19 % 7 36 % 13 44 % 16 23 23 % 64 % 71 % 5 69 % 9 31 % 5 6 % 4
Netherlands 38 % 38 13 % 5 74 % 28 13 % 5 30 30 % 79 % 20 % 1 75 % 21 40 % 2 10 % 6
Sweden 43 % 43 95 % 41 0 % 0 5 % 2 41 41 % 95 % 100 % 41 0 % 0 0 % 0 0 % 0
Scotland 60 % 61 51 % 31 2 % 1 48 % 29 11 11 % 18 % 19 % 6 0 % 0 10 % 3 5 % 2
Wales 67 % 68 28 % 19 9 % 6 63 % 43 13 13 % 19 % 32 % 6 0 % 0 12 % 5 6 % 2
France 74 % 75 85 % 64 9 % 7 5 % 4 20 20 % 27 % 30 % 19 0 % 0 25 % 1 0 % 0
Source: Authors’ own calculations based on information from the websites of the eight HTA agencies
Notes: aCountries ordered according to the share of assessed orphan drugs (from lowest to highest)
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drugs (5 and 7, respectively) and France the highest
(64), followed by Sweden (41) and Scotland (31).
However, in most countries, the number of reim-
bursed orphan drugs was much lower than the num-
ber of positive HTA recommendations (e.g. 20 vs. 64
for France). In England, Poland and in the
Netherlands the number of reimbursed orphan drugs
was higher than the number of positive recommenda-
tions (Table 2).
On average, 21.2 % of the total of 101 orphan drugs
studied (i.e. EMA-approved orphan drugs) were reim-
bursed in the European countries. The highest rate of
reimbursed orphan drugs was observed in Sweden
(40.6 %) and the Netherlands (29.7 %). The lowest
rate was reported in Scotland (10.9 %). In terms of
the share of reimbursed orphan drugs in the total
number of assessed orphan drugs, the highest values
were observed in Sweden (95 %), Germany (80 %)
and the Netherlands (79 %) and the lowest in
Scotland (18 %), Wales (19 %) and France (27 %)
(Table 2).
The highest rate of reimbursement was observed for
drugs that obtained a positive or conditional recom-
mendation from a HTA agency (49.0 % and 53.6 %,
respectively (for all countries), compared to 16.0 %
for negative recommendations). Poland and the
England
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Wales
France
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Fig. 2 Relationship between the share (%) of assessed orphan drugs (x-axis) and the share (%) of assessed drugs with positive and conditional
HTA recommendations (y-axis). Source: Authors’ own calculations based on information from the websites of the eight HTA agencies. Note:
Countries where there are special criteria for orphan drugs in the HTA process are marked in bold
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Fig. 3 Share (%) of positive and conditional HTA recommendations, by country. Source: Authors based on information from the websites of the
eight HTA agencies. Note: Countries where there are special criteria for orphan drugs in the HTA process are marked in black
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Netherlands were the countries where the highest
shares of drugs with a negative recommendation (31.3
% and 40.0 % of drugs, respectively) were reimbursed
from public funds. On average, 5.4 % of orphan drugs
that have never been assessed by any HTA agency
were reimbursed (Table 2).
Ultra-orphan, oncology, non-ultra and non-oncology or-
phan drugs
Among the 101 identified orphan drugs, 18 (17.8 %) were
classified as ultra-orphan, 34 (33.7 %) were registered with
oncologic indications and 50 (49.5 %) were non-ultra and
non-oncology orphan drugs. The eight HTA agencies
evaluated between 5.6 % (England, Germany) and 72.2 %
(Wales, France) of all identified ultra-orphan drugs, be-
tween 32.4 % (Germany, Netherlands) and 76.5 % (France)
of all identified oncology orphan drugs and between 14.0
% (England) and 74.0 % (France) of all non-ultra and non-
oncology orphan drugs. Among the ultra-orphan, the
oncology and the non-ultra and non-oncology orphan
drugs, 5 (28 %), 7 (21 %) and 10 (20 %), respectively,
have never been assessed by any of the eight HTA
agencies.
The highest rate of reimbursed drugs with positive
HTA recommendations is observed among ultra-orphan
drugs (53 %), while among other groups this rate ranges
from 46 % (oncology orphan drugs) to 49 % (non-ultra,
non-oncology orphan drugs). About 5 % of drugs which
have never been assessed by an HTA agency is reim-
bursed from public funds. This rate is much higher for
ultra-orphan drugs - 11 % (Table 3).
In terms of access to ultra, oncology, non-ultra and
non-oncology orphan drugs, the highest rate of reim-
bursement is observed in ultra-orphan drugs (25 %).
In other groups, i.e. oncology orphan drugs and non-
ultra, non-oncology orphan drugs this rate is around
20–21 %. Poland has the highest rate of reimburse-
ment for ultra-orphan drugs (50 %) while Germany
has the lowest (6 %). In Sweden, 47 % of oncology-
orphan drugs are reimbursed from public funds and
only 6 % of such drugs are reimbursed in England,
Wales and Scotland. The highest rate of reimburse-
ment for non-ultra, non-oncology orphan drugs is
observed in Sweden (36 %) and the lowest in
Scotland (10 %).
The average rates of positive, conditional and nega-
tive recommendations issued by all HTA agencies for
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Fig. 4 Share (%) of all assessed orphan drugs that are reimbursed, by country. Source: Authors based on information from the websites of the
eight HTA agencies. Note: Countries where there are special criteria for orphan drugs in the reimbursement decision process are marked in black
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Fig. 5 Share (%) of orphan drugs that have never been assessed by any of the HTA Agency considered that are reimbursed, by country. Source:
Authors based on information from the websites of the eight HTA agencies. Note: Countries with special criteria for orphan drugs in the
reimbursement decision process are marked in black
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Table 3 Share (%) of reimbursed ultra-orphan, oncology orphan and other orphan drugs by type of HTA recommendation, by country
All orphan (101) Ultra-orphan Oncology orphan Non-ultra, non-oncology orphan drugs
Positive Conditional Negative Not
assessed
Positive Conditional Negative Not
assessed
Positive Conditional Negative Not
assessed
Positive Conditional Negative Not
assessed
England 25 % 0 % 14 % 11 % 0 % 0 % 0 % 24 % 33 % 0 % 0 % 0 % 20 % 0 % 50 % 12 %
Germany 76 % 0 % 0 % 1 % 100 % 0 % 0 % 0 % 73 % 0 % 0 % 0 % 77 % 0 % 0 % 3 %
Poland 71 % 69 % 31 % 6 % 100 % 100 % 50 % 27 % 100 % 67 % 38 % 0 % 33 % 57 % 17 % 3 %
Netherlands 20 % 75 % 40 % 10 % 0 % 75 % 100 % 8 % 0 % 83 % 33 % 17 % 33 % 72 % 0 % 7 %
Sweden 100 % 0 % 0 % 0 % 100 % 0 % 0 % 0 % 100 % 0 % 0 % 0 % 100 % 0 % 0 % 0 %
Scotland 19 % 0 % 10 % 5 % 40 % 0 % 20 % 13 % 9 % 0 % 0 % 8 % 19 % 0 % 14 % 0 %
Wales 32 % 0 % 12 % 6 % 60 % 0 % 0 % 20 % 13 % 0 % 10 % 0 % 29 % 0 % 16 % 7 %
France 30 % 0 % 25 % 0 % 18 % 0 % 0 % 0 % 36 % 0 % 0 % 0 % 35 % 0 % 25 % 0 %
All
countriesa
49 % 54 % 16 % 5 % 53 % 67 % 19 % 11 % 46 % 41 % 14 % 4 % 49 % 57 % 17 % 5 %
Source: Authors based on information from the websites of the eight HTA agencies; a calculated as the sum of all reimbursed drugs with particular type of recommendation (positive/conditional/negative/no
recommendation) from all agencies divided by the sum of all drugs (reimbursed and not reimbursed) with particular type of recommendation from all agencies
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ultra-orphan drugs were 56.1 %, 15.8 % and 28.1 %,
respectively. The highest rate of positive recommen-
dations for ultra-orphan drugs was seen in England,
Sweden and Germany (100 %) and the lowest in the
Netherlands (0 %); however, the Dutch ZIN issued 80
% of conditional recommendations for ultra-orphan
drugs. The average rates of positive, conditional and
negative recommendations for oncology orphan drugs
were, respectively, 60.2 %, 12.8 % and 27.1 %. The
highest rate of positive recommendations for oncology
orphan drugs was observed in Sweden and Germany
(100 %) and the lowest in the Netherlands (18.18 %).
In case of non-ultra and non-oncology orphan drugs
the average rates of positive, conditional and negative
recommendations were, respectively, 53.3 %, 16.7 %
and 30.0 % (Fig. 6). The highest rate of positive
recommendations for above group of drugs was
observed in Germany (100 %) and the lowest in the
Netherlands (13.64 %).
On average, 25 % of EMA-authorized ultra-orphan
drugs, 19.9 % of oncology orphan drugs, 20.8 % of
non-ultra and non-oncology orphan drugs were
reimbursed in the eight countries. The shares of
reimbursed ultra-orphan drugs and non-ultra, non-
oncology orphan drugs in the total number of such
drugs with positive, conditional and negative reim-
bursement recommendations (and in the total number
of not assessed ultra-orphan drugs) were on average
higher than the respective shares for oncology orphan
drugs (Fig. 7).
Discussion
In many European countries HTA is used to assess
the value of new technologies, including orphan
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Fig. 6 Share (%) of positive, conditional and negative HTA recommendations for ultra-orphan drugs, oncology orphan drugs as well as non-ultra
non-oncology drugs; by country. Source: Author’s own calculations based on data from the websites of the eight HTA agencies
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drugs. This is usually more difficult for orphan com-
pared to non-orphan drugs because reliable clinical
and economic evidence required for this purpose is
often unavailable for the former due to small num-
bers of patients. This is despite incentives for
pharmaceutical companies to develop such products
and the use of less stringent criteria for trials of
drugs with designated orphan indications [11].
Based on our research it appears that the higher the
number of assessed drugs, the lower the number of
positive and conditional HTA recommendations. Some
of countries (France, Scotland) apply special criteria to
orphan drugs in the HTA process or while deciding on
the reimbursement (Netherlands, Sweden) or both
(Germany) (Table 4). There seems to be a positive cor-
relation between the existence of such special HTA
Table 4 Special HTA and reimbursement considerations for orphan drugs
Country Special HTA considerations for orphan drugs Special reimbursement considerations for orphan drugs
Germany • Certain special HTA criteria are applied to orphan drugs:
- Higher p-values for small sample sizes
- Use of surrogate endpoints
- Additional benefit is considered proven at marketing
authorization (MA) if the budget impact is less than €50 million
per year for a particular indicationa
• Higher therapeutic benefit is automatically recognized for orphan
drugs (Section 35a, para. 1 clause 10 of the German Social Code
Book V), since these drugs had to prove significant additional
therapeutic benefit compared to other possibly already approved
drugs as part of the European marketing authorization procedure
• The ascertainment of an additional benefit, which is automatic
for orphan drugs, is also binding for subsequent administrative
acts, which includes reimbursement decisions by the G-BA (body
issuing reimbursement decisions)
• IQWiG (body issuing HTA recommendations) only assesses target
population size and drug budget impact to all population, and the
G-BA decides only on the extent of additional benefit (this applies
to all drugs, not only orphan drugs)
• While there are no specific pricing considerations for orphan
drugs, the latter are often characterized as having no therapeutic
alternatives (by G-Ba and IQWiG) - this makes comparison with
existing therapies impossible and means free pricing in practice
France • Certain special HTA criteria are applied to orphan drugs:
- Additional benefit is considered proven at MA if the budget
impact is less than €30 million per year for a particular indication
- Accelerated HTA procedure is available for all innovative drugs
(not only for orphan drugs)
• The Ministry of Health decides on the reimbursement of the
drug, taking into the SMR and ASMR considerations
• The Agency for the Sanitary Security of Health Products (Agence
Française de Sécurité Sanitaire des Produits de Santé) can issue
authorization for temporary use in case of life-threatening condi-
tions or/and when there is no therapeutic alternative (this is not
specific to orphan drugs but can be applied to them)
None
Netherlands None • Hospitals may apply for full additional funding for orphan drugs
that are prescribed within their institution. The additional
temporally funding considers therapeutic value, cost prognosis and
outcomes research – treatment of all patients need to be
documented in a patient registry
• In case of orphan drugs the therapeutic value, the severity of the
disease and the efficient prescription will be important for the
decision on definitive listing/ funding
Poland None None
Sweden None • TLV (body issuing reimbursement decisions) usually accepts a
higher willingness-to-pay threshold for treatment of severe condi-
tions; the human value principle implies equality of all people,
while the principles of need and solidarity imply that conditions
for which there is a greater need take precedence over others; in
practice this means a higher cost-effectiveness threshold may be
considered for orphan drugs
England None None
Scotland • Certain special HTA criteria are applied to orphan drugs:
- Lower levels of evidence are accepted for clinical trials (e.g., on
efficacy and safety) and in economic evaluations
- Additional data may be required (e.g., surrogate markers and
quality-of-life data)
None
Wales None None
Sources: [2–10]
Notes: aWith the exception of orphan drugs, the new Pharmaceutical Market Reorganisation Act of 2010 made the early evaluation of the additional benefit of a
pharmaceutical product by the G-BA mandatory after MA; nevertheless, manufacturers of orphan drugs need to submit a dossier so that the G-BA can assess the
level of additional benefit and use this in price negotiations, if needed [6]. MA marketing authorization
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criteria and the shares of orphan drugs with positive or
negative HTA recommendations and between the exist-
ence of special criteria in the reimbursement process
and the shares of orphan drugs that are actually reim-
bursed. As it was not an objective of our analysis, we
suggest further studies on this topic in a future.
In terms of HTA rejection rates (probability of nega-
tive HTA recommendations), Mardiguian et al. [12]
found that NICE in England had the highest rejection
rate (40 %) while SMC in Scotland had one of the lowest
rejection rates (30 %) among the five countries consid-
ered (Australia, Canada, England, Scotland and Wales).
In our analysis we found that England had a lower rejec-
tion rate than Scotland (35 % compared to 47.5 %). This
is likely explained by the fact that our sample size (101
drugs) was much higher than that of Mardiguian and
colleagues (29 drugs) but comparisons of countries with
different healthcare systems (England vs. Australia or
Canada) should be performed with caution. Mycka et al.
[13] compared orphan drugs assessment in Germany
with HTA agencies in five other countries. However, also
in this case it is difficult to compare their results with
the results of our analysis given the differences in the
sample sizes (19 vs. 101) and healthcare systems. To our
best knowledge no other evaluations referring to the
types of HTA agencies’ recommendations or the rela-
tionship between the type of HTA recommendations
and the reimbursement status of drugs were performed
and published elsewhere
While more than 78 % of approved orphan drugs have
been assessed by the European HTA agencies, only a
fifth of them (21 %) is reimbursed from public funds.
While this also applies to oncology orphan drugs (79 %
have been assessed and 20 % have been reimbursed) and
non-ultra, non-oncology orphan drugs (80 % and 21 %,
respectively), the share of ultra-orphan drugs that are re-
imbursed is higher (25 %) (72 % of identified ultra-
orphan drugs have been assessed by the HTA agencies).
This may be because the likelihood of being able to use
an alternative treatment for ultra-orphan diseases is
much lower than for non-ultra-orphan diseases. Coun-
tries that have special criteria for orphan drugs in the re-
imbursement processes appear to have higher shares of
assessed drugs that are reimbursed from public funds;
however, this relationship has not been tested in anyway.
It should be noticed that reimbursement recommenda-
tions and reimbursement status of drugs are not the same
aspects. Due to financial limitations on reimbursement
and increasing costs of pharmacotherapy an aggregating
difference between positive recommendations and positive
reimbursement decisions (what means a real access to
pharmacotherapy) is observed in various countries.
Moreover, in majority of European countries no reim-
bursement is possible for orphan drugs without previous
HTA assessment, which is a tool providing decision
makers useful information on clinical efficacy, costs and
cost-effectiveness of drugs and let allocate public cover-
age on pharmacotherapy which should be reimbursed in
the lack of sufficient financial resources; we speculate
that in coming years in all EU member states such as-
sessment for orphan drugs should be obligatory. On the
other hand in some countries (e.g. Poland) some
changes of too strict reimbursement requirements for
orphan drugs are about to be implemented; currently in
Poland tjust the same reimbursement procedures as for
drugs used in non-rare diseases have been applied for
orphans but probably in coming months a new law will
be launched in Poland with a submission of a justifica-
tion of the proposed price of orphan drug instead of
submitting a full economic analysis. This means that the
cost-effectiveness analyses for orphan drugs will no lon-
ger be obligatory but clinical analysis as well as budget
impact analysis should still be submitted during applica-
tion for reimbursement of orphan drugs in Poland. The
similar approach to the orphan drugs’ assessment is ob-
served in France – HAS does not examine the economic
evidence in a reimbursement process [14]. In Germany
there is a lower accepted significance level for p-values
in case of assessment of orphan drugs’ clinical outcomes
(when sample size is small) and there is an acceptance of
evidence from surrogate endpoints. The economic ana-
lysis is not required if the budget impact is less than 50
million euro per annum [4]. Lower levels of evidence are
accepted for clinical trials for orphan drugs in Scotland
and higher cost per QALY than threshold value for non-
orphan drugs is accepted in economic analysis. The
flexibility in willingness-to-pay threshold value in case of
orphan drugs is also acceptable in Sweden [4].
Conclusions
The reimbursement status does not always correspond
to the type of the recommendation issued by an HTA
agency for an orphan drug. The highest rate of reim-
bursement is observed among drugs with positive or
conditional recommendation, but high rate of reim-
bursement is also observed among ultra-orphan drugs
that had never been assessed by any HTA agency.
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